Clear All
716 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
HCPCS Generic Name Brand Name Strength SEER*Rx Category Major Drug Class Minor Drug Class Oral (Y/N) FDA Approval Year FDA Discontinuation Year CMS Effective Date CMS Discontinuation Date Status
NA Nilutamide Anadron, Nilandron 150 mg Hormonal Therapy Androgen Receptor Inhibitor Yes 1996 In Use
NA Nilotinib Tasigna 150 mg Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Yes 2007 In Use
NA Nilotinib Tasigna 200 mg Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Yes 2007 In Use
Q9978 Netupitant/palonostron Akynzeo 300mg/0.5 mg Ancillary Therapy Antiemetic 5HT3 Receptor Anatagonist/Substance P/Neurokinin 1 Yes 2014 Jul 1, 2015 Dec 31, 2015 No Longer Used
J8655 Netupitant/palonostron Akynzeo 300mg/0.5 mg Ancillary Therapy Antiemetic 5HT3 Receptor Anatagonist/Substance P/Neurokinin 1 Yes 2014 Jan 1, 2016 In Use
C9448 Netupitant/Palonosetron Akynzeo 300mg/0.5 mg Ancillary Therapy Antiemetic 5HT3 Receptor Anatagonist/Substance P/Neurokinin 1 Yes 2014 Apr 1, 2015 Jun 30, 2015 No Longer Used
NA Neratinib Nerlynx 40 mg Chemotherapy Tyrosine Kinase Inhibitor EGFR/HER2 Yes 2017 In Use
J9261 Nelarabine Arranon 50 mg Chemotherapy Antimetabolite Purine Analog No 2005 Jan 1, 2007 In Use
J9295 Necitumumab Portrazza 1 mg Immunotherapy Monoclonal Antibody EGFR No 2015 Jan 1, 2017 In Use
C9475 Necitumumab Portrazza 1 mg Immunotherapy Monoclonal Antibody EGFR No 2015 Apr 1, 2016 In Use
J9348 Naxitamab Danyelva 1mg Immunotherapy Monoclonal Antibody GD2 No 2020 Jul 23, 2021 In Use
NA Naldemedine Symproic 0.2mg Ancillary Therapy Opioid Antagonist Yes 2018 In Use
J8650 Nabilone Cesamet 1 mg Ancillary Therapy Antiemetic Cannabinoid Yes 1985 Jan 1, 2007 In Use
J9313 Moxetumomab-pasudotox-tdfk Lumoxiti 0.01mg Immunotherapy Drug Antibody Conjugate CD22 No 2018 Oct 1, 2019 In Use
J2277 Motixafortide Motixafortide 0.25mg Ancillary Therapy Immunostimulant Stem cell mobilizer No 2023 Apr 17, 2024 In Use
J9350 Mosunetuzumab-axgb Lunsumio 1mg Immunotherapy Monoclonal Antibody CD20, CD3 No 2022 Jul 11, 2023 In Use
Momelotinib Ojjaara Multiple Chemotherapy Enzyme Inhibitor JAK 1/2 Yes 2023 In Use
J9204 Mogamulizumab-kpkc Poteligeo 1mg Immunotherapy Monoclonal Antibody CCR4 No 2018 Oct 1, 2019 In Use
Mobocertinib Exkivity 40mg Chemotherapy Tyrosine Kinase Inhibitor EGFR Yes 2021 In Use
J9293 Mitoxantrone Mitoxantrone pr 5 mg Chemotherapy Antitumor Antibiotic Anthracenedione No 1987 Jan 1, 1990 In Use
NA Mitotane Lysodren unspecified Chemotherapy Miscellaneous Agent Adrenal Suppressant Yes 1970 In Use
C9432 Mitomycin Mitosol 5 mg Chemotherapy Antitumor Antibiotic Alkylating Agent/ Mitomycin No 1981 Jan 1, 2004 Dec 31, 2005 No Longer Used
J9280 Mitomycin Mitosol 5 mg Chemotherapy Antitumor Antibiotic Alkylating Agent/ Mitomycin No 1981 Jan 1, 1986 In Use
J9291 Mitomycin Mitosol 40 mg Chemotherapy Antitumor Antibiotic Alkylating Agent/ Mitomycin No 1981 Jan 1, 1989 Dec 31, 2010 No Longer Used
J9290 Mitomycin Mitosol 20 mg Chemotherapy Antitumor Antibiotic Alkylating Agent/ Mitomycin No 1981 Jan 1, 1994 Dec 31, 2010 No Longer Used
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is truly not available.